Nafamostat in hospitalized patients with moderate to severe COVID-19 pneumonia: a randomised Phase II clinical trial

BACKGROUND: Nafamostat, a serine protease inhibitor, has been used for the treatment of disseminated intravascular coagulation and pancreatitis. In vitro studies and clinical reports suggest its beneficial effect in the treatment of COVID-19 pneumonia. METHODS: This phase 2 open-label, randomised, m...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhuravel, Sergey V, Khmelnitskiy, Oleg K, Burlaka, Oleg O, Gritsan, Alexey I, Goloshchekin, Boris M, Kim, Seieun, Hong, Ka Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548051/
https://www.ncbi.nlm.nih.gov/pubmed/34723164
http://dx.doi.org/10.1016/j.eclinm.2021.101169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8548051/
https://www.ncbi.nlm.nih.gov/pubmed/34723164
http://dx.doi.org/10.1016/j.eclinm.2021.101169

Ejemplares similares